23 completed, 4 recruiting, 2 terminated, 2 unknown. 33 Phase 2, 7 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 33 | Completed 23, Recruiting 4, Terminated 2, Unknown 2, Not yet recruiting 1, Withdrawn 1 |
| Phase 1 | 7 | Completed 5, Recruiting 1, Withdrawn 1 |
| Phase 3 | 1 | Completed 1 |
Follow Vehicle Control: new trials by email Literature Review of Vehicle Control trials Research Report on Vehicle Control
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 2 Study to Assess the Effectiveness of Topical Terbinafine in Participants With Mild to Moderate Onychomycosis of the Toenails 2.4% Topical Terbinafine, 10% Topical Efinaconazole, Vehicle Control - Onychomycosis of Toenail | Phase 2 | Not yet recruiting | Onyx Axiom | 200 | 2026-03-01 | 2026-02-04 |
| A PHASE II PROSPECTIVE RANDOMIZED DOUBLE-MASKED CROSSOVER STUDY ASSESSING THE SAFETY & EFFICACY OF RHPRG4 (450 μG/ML RECOMBINANT HUMAN PROTEOGLYCAN 4) COMPARED TO VEHICLE FOR THE TREATMENT OF OCULAR GRAFT-VERSUS-HOST DISEASE (OGVHD) rhPRG4 450ug/ml, Vehicle Control - Ocular Graft Versus Host Disease | Phase 2 | Recruiting | Lubris Bio Pty Ltd | 15 | 2025-09-17 | 2026-10-26 |
| A PHASE II PROSPECTIVE RANDOMIZED DOUBLE-MASKED CONTROLLED STUDY ASSESSING THE SAFETY & EFFICACY OF RHPRG4 (450 µG/ML RECOMBINANT HUMAN PROTEOGLYCAN 4) COMPARED TO VEHICLE FOR THE TREATMENT OF SJÖGREN'S RELATED DRY EYE DISEASE Recombinant Human Proteoglycan 4, Vehicle Control - Sjögren's Syndrome | Phase 2 | Recruiting | Lubris Bio Pty Ltd | 80 | 2025-09-17 | 2026-10-28 |
| Efficacy of Topical Mesenchymal Stromal Cell Secretome for Ocular Surface Disease Allogeneic Bone-Marrow Derived Mesenchymal Stromal Cells Secretome, Vehicle Control - Persistent Corneal Epithelial Defect, Corneal Epithelial Disorders | Phase 2 | Recruiting | University of Illinois Chicago | 24 | 2025-08-01 | 2026-10-28 |
| A Study to Investigate the Safety and Efficacy of YY003 in Adults With Moderate to Severe Glabellar Lines YY003, Vehicle Control - Moderate to Severe Glabellar Lines | Phase 2 | Completed | Chongqing Claruvis Pharmaceutical Co., Ltd. | 153 | 2025-01-09 | 2026-09-08 |
| CBD for Knee Osteoarthritis Cannabidiol (CBD) Extract, Placebo - Osteoarthritis, Knee | Phase 1 / Phase 2 | Recruiting | University of Florida | 30 | 2024-06-14 | 2025-09-17 |
| Study to Evaluate Safety and Efficacy of ALLO-ASC-SHEET in Subjects With Dystrophic Epidermolysis Bullosa ALLO-ASC-SHEET, Vehicle Control - Dystrophic Epidermolysis Bullosa | Phase 2 | Unknown | Anterogen Co., Ltd. | 6 | 2023-05-01 | 2024-04-22 |
| Nesvategrast (OTT166) in Diabetic Retinopathy (DR) OTT166, Vehicle control - Diabetic Retinopathy | Phase 2 | Completed | OcuTerra Therapeutics, Inc. | 225 | 2022-07-29 | 2024-08-09 |
| Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Neurotrophic Keratitis Subjects CSB-001 Ophthalmic Solution 0.1%, Vehicle Control - Neurotrophic Keratitis | Phase 1 / Phase 2 | Completed | Claris Biotherapeutics, Inc. | 131 | 2021-08-24 | 2026-05-13 |
| A Study of ORTD-1 in Patients Hospitalized With COVID-19 Related Pneumonia ORTD-1 low dose, ORTD-1 mid dose, ORTD-1 high dose - COVID-19 | Phase 1 / Phase 2 | Withdrawn | Oryn Therapeutics, LLC | 2021-04-01 | 2021-06-14 | |
| A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19 APL-9, Vehicle Control - COVID, Covid-19 | Phase 1 / Phase 2 | Completed | Apellis Pharmaceuticals, Inc. | 72 | 2020-05-28 | 2022-03-23 |
| Evaluation of the Safety and Efficacy Study of RGN-137 Topical Gel for Junctional and Dystrophic Epidermolysis Bullosa RGN-137, Placebo - Junctional Epidermolysis Bullosa, Dystrophic Epidermolysis Bullosa | Phase 2 | Terminated | Lenus Therapeutics, LLC | 4 | 2019-05-22 | 2022-08-22 |
| SINGLE-APPLICATION TERBINAFINE HYDROCHLORIDE (1%) TOPICAL LIQUID SOLUTION VERSUS A SINGLE-APPLICATION BUTENAFINE HYDROCHLORIDE (1%) TOPICAL LIQUID SOLUTION FOR THE TREATMENT OF TINEA PEDIS TERBINAFINE HYDROCHLORIDE (1%), BUTENAFINE HYDROCHLORIDE (1%), Vehicle Control - Tinea Pedis | Phase 2 | Unknown | United Laboratories | 42 | 2019-01-02 | 2019-06-26 |
| Topical Fibrinogen-Depleted Human Platelet Lysate in Patients With Dry Eye Secondary to Graft vs. Host Disease CAM-101 10%, Vehicle Control, CAM-101 30% - Dry Eye, Graft-versus-host-disease | Phase 1 / Phase 2 | Completed | Cambium Bio Limited | 64 | 2018-05-01 | 2026-06-12 |
| Evaluation of the Antimicrobial Effectiveness of an Antimicrobial Cloth Octenidine Dihydrocloride in aqueous solution, Vehicle Control, Saline Control - Preoperative Skin Preparation | Phase 2 | Completed | Becton, Dickinson and Company | 99 | 2017-06-21 | 2021-04-23 |
| Pain Study to Assess Local Anesthetic Efficacy and Safety of CTY-5339 on Gingival Mucosal Tissue in Normal Volunteers One spray CTY-5339-A, One spray CTY-5339-CB, One spray CTY-5339-P - No Disease State or Condition | Phase 2 | Completed | Cetylite Industries | 75 | 2017-06-15 | 2019-08-21 |
| DMT210 Topical Gel in the Treatment of Acne Rosacea DMT210 Topical Gel 5%, Vehicle Control - Acne Rosacea | Phase 2 | Completed | Dermata Therapeutics | 107 | 2017-01-01 | 2018-04-18 |
| DMT210 Topical Gel in the Treatment of Atopic Dermatitis DMT210 Topical Gel, Vehicle Control - Atopic Dermatitis | Phase 2 | Completed | Dermata Therapeutics | 19 | 2016-10-01 | 2018-04-18 |
| Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-1 RGN-259, Placebo - Dry Eye Syndrome | Phase 2 / Phase 3 | Completed | ReGenTree, LLC | 317 | 2015-09-01 | 2019-10-17 |
| Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD) Squalamine lactate, Vehicle control - Neovascular Age Related Macular Degeneration | Phase 2 | Completed | Ohr Pharmaceutical Inc. | 142 | 2012-11-01 | 2015-06-12 |
Showing 20 of 33. Sign in to see all of them.
Dry Eye Syndromes (6) · Graft vs Host Disease (3) · Acne Vulgaris (2) · COVID-19 (2) · Epidermolysis Bullosa Dystrophica (2) · Intervertebral Disc Degeneration (2) · Sjogren's Syndrome (2) · Skin Diseases (2) · Acute Lung Injury (1) · Arthritis, Rheumatoid (1) · Back Pain (1) · Burns (1) · Carcinoma, Non-Small-Cell Lung (1) · Cardiomyopathy, Dilated (1) · Coronavirus Infections (1)
Bausch Health Americas, Inc. (2) · Dermata Therapeutics (2) · Lubris Bio Pty Ltd (2) · ReGenTree, LLC (2) · Allergan (1) · Anterogen Co., Ltd. (1) · Apellis Pharmaceuticals, Inc. (1) · Becton, Dickinson and Company (1) · Cambium Bio Limited (1) · Celularity Incorporated (1) · Cetylite Industries (1) · Chongqing Claruvis Pharmaceutical Co., Ltd. (1) · Claris Biotherapeutics, Inc. (1) · Critical Biologics Corporation (1) · DePuy Spine (1)
United States (25) · Australia (4) · Canada (2) · Brazil (1) · Hong Kong (1) · Philippines (1) · Puerto Rico (1) · South Korea (1)
Gail Torkildsen, MD (2) · Ali R Djalilian, MD (1) · Alicia Barba, MD (1) · Alicia Bucko, DO (1) · Alpesh Amin, MD (1) · Ana Rossi, MD (1) · Brock McConnehey,, DO (1) · Carl Regillo, MD (1) · Charles Lynde, MD (1) · Christopher Beausoleil (1) · Christopher Nardo, PhD (1) · Dan Stewart, DO (1) · David Gratton, MD (1) · David Pariser, MD (1) · Edmund K Waller, MD PhD (1)
PMID 22712470, PMID 25142002, PMID 25826322, PMID 25985246, PMID 30660443, PMID 33945627, PMID 35266655
3UH3EY031809-04S1 (1)